PROTECTING POOR METABOLISERS, A GROUP AT HIGH RISK OF ADVERSE DRUG REACTIONS
- 18 June 1983
- journal article
- other
- Published by Elsevier in The Lancet
- Vol. 321 (8338) , 1388
- https://doi.org/10.1016/s0140-6736(83)92172-4
Abstract
No abstract availableThis publication has 12 references indexed in Scilit:
- Genetically determined oxidation capacity and the disposition of debrisoquine.British Journal of Clinical Pharmacology, 1983
- Oxidation Phenotype — A Major Determinant of Metoprolol Metabolism and ResponseNew England Journal of Medicine, 1982
- HIGH PLASMA CONCENTRATIONS OF β-RECEPTOR BLOCKING DRUGS AND DEFICIENT DEBRISOQUINE HYDROXYLATIONThe Lancet, 1982
- BETA-BLOCKERS AND DRUG OXIDATION STATUSThe Lancet, 1982
- Impaired oxidation of debrisoquine in patients with perhexiline neuropathy.BMJ, 1982
- Pharmacokinetics of perhexiline maleate in anginal patients with and without peripheral neuropathyEuropean Journal of Clinical Pharmacology, 1978
- Polymorphism of carbon oxidation of drugs and clinical implications.BMJ, 1978
- PERCUTANEOUS LIVER BIOPSY AND CHRONIC LIVER DISEASE IN HÆMOPHILIACSThe Lancet, 1978
- Hypotensive response to debrisoquine and hydroxylation phenotypeLife Sciences, 1978
- Health of the intensively treated hemophiliac, with special reference to abnormal liver chemistries and splenomegalyBlood, 1977